Header Logo

Connection

NIKOLAOS FRANGOGIANNIS to Humans

Back to Details
This is a "connection" page, showing publications NIKOLAOS FRANGOGIANNIS has written about Humans.
NIKOLAOS FRANGOGIANNIS
Connection Strength
1.001
Humans
  1. Response by Frangogiannis to Letter Regarding Article, "Cardiac Pericytes Acquire a Fibrogenic Phenotype and Contribute to Vascular Maturation After Myocardial Infarction". Circulation. 2024 03 19; 149(12):e962-e963.
    View in: PubMed
    Score: 0.019
  2. TGF-? as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities. Expert Opin Ther Targets. 2024 Jan-Feb; 28(1-2):45-56.
    View in: PubMed
    Score: 0.019
  3. Targeting galectin-3 in myocardial infarction: a unique opportunity for biomarker-guided therapy. Cardiovasc Res. 2023 11 25; 119(15):2495-2496.
    View in: PubMed
    Score: 0.019
  4. Cardiac Pericytes Acquire a Fibrogenic Phenotype and Contribute to Vascular Maturation After Myocardial Infarction. Circulation. 2023 09 12; 148(11):882-898.
    View in: PubMed
    Score: 0.018
  5. Macrophages in myocardial infarction. Am J Physiol Cell Physiol. 2022 10 01; 323(4):C1304-C1324.
    View in: PubMed
    Score: 0.017
  6. Integrins in cardiac fibrosis. J Mol Cell Cardiol. 2022 Nov; 172:1-13.
    View in: PubMed
    Score: 0.017
  7. Smad-dependent pathways in the infarcted and failing heart. Curr Opin Pharmacol. 2022 06; 64:102207.
    View in: PubMed
    Score: 0.017
  8. Transforming growth factor-? in myocardial disease. Nat Rev Cardiol. 2022 07; 19(7):435-455.
    View in: PubMed
    Score: 0.016
  9. Platelet-derived growth factor (PDGF) therapy in myocardial infarction: Challenges and opportunities. Int J Cardiol. 2021 10 15; 341:74-75.
    View in: PubMed
    Score: 0.016
  10. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021 09; 176:113904.
    View in: PubMed
    Score: 0.016
  11. Cardiac fibrosis. Cardiovasc Res. 2021 05 25; 117(6):1450-1488.
    View in: PubMed
    Score: 0.016
  12. Diabetic fibrosis. Biochim Biophys Acta Mol Basis Dis. 2021 04 01; 1867(4):166044.
    View in: PubMed
    Score: 0.015
  13. The role of Smad signaling cascades in cardiac fibrosis. Cell Signal. 2021 01; 77:109826.
    View in: PubMed
    Score: 0.015
  14. Fact and Fiction About Fibroblast to Endothelium Conversion: Semantics and Substance of Cellular Identity. Circulation. 2020 10 27; 142(17):1663-1666.
    View in: PubMed
    Score: 0.015
  15. The significance of COVID-19-associated myocardial injury: how overinterpretation of scientific findings can fuel media sensationalism and spread misinformation. Eur Heart J. 2020 10 14; 41(39):3836-3838.
    View in: PubMed
    Score: 0.015
  16. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther. 2020 12; 34(6):849-863.
    View in: PubMed
    Score: 0.015
  17. Chemokines in Myocardial Infarction. J Cardiovasc Transl Res. 2021 02; 14(1):35-52.
    View in: PubMed
    Score: 0.015
  18. Extracellular matrix-derived peptides in tissue remodeling and fibrosis. Matrix Biol. 2020 09; 91-92:176-187.
    View in: PubMed
    Score: 0.015
  19. Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC?Focus Seminar. J Am Coll Cardiol. 2020 05 05; 75(17):2219-2235.
    View in: PubMed
    Score: 0.015
  20. The role of Smad2 and Smad3 in regulating homeostatic functions of fibroblasts in vitro and in adult mice. Biochim Biophys Acta Mol Cell Res. 2020 07; 1867(7):118703.
    View in: PubMed
    Score: 0.014
  21. Transforming growth factor-? in tissue fibrosis. J Exp Med. 2020 03 02; 217(3):e20190103.
    View in: PubMed
    Score: 0.014
  22. Monocyte subsets as predictors of adverse events in patients with atherosclerosis. Hellenic J Cardiol. 2019 Sep - Oct; 60(5):322-323.
    View in: PubMed
    Score: 0.014
  23. Editorial commentary: Myocardial fibrosis in genetic cardiomyopathies: A cause of dysfunction, or simply an epiphenomenon? Trends Cardiovasc Med. 2020 08; 30(6):362-363.
    View in: PubMed
    Score: 0.014
  24. How do endosomal Toll-like receptors sense and extend ischaemic myocardial injury? Cardiovasc Res. 2019 10 01; 115(12):1687-1689.
    View in: PubMed
    Score: 0.014
  25. S100A8/A9 as a therapeutic target in myocardial infarction: cellular mechanisms, molecular interactions, and translational challenges. Eur Heart J. 2019 08 21; 40(32):2724-2726.
    View in: PubMed
    Score: 0.014
  26. The cell biological basis for primary unloading in acute myocardial infarction. Int J Cardiol. 2019 10 15; 293:45-47.
    View in: PubMed
    Score: 0.014
  27. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019 06 21; 125(1):117-146.
    View in: PubMed
    Score: 0.014
  28. Can Myocardial Fibrosis Be Reversed? J Am Coll Cardiol. 2019 05 14; 73(18):2283-2285.
    View in: PubMed
    Score: 0.014
  29. The Functional Heterogeneity of Resident Cardiac Macrophages in Myocardial InjuryCCR2+ Cells Promote Inflammation, Whereas CCR2- Cells Protect. Circ Res. 2019 01 18; 124(2):183-185.
    View in: PubMed
    Score: 0.013
  30. Protean Functions and Phenotypic Plasticity of Regulatory T Cells in Chronic Ischemic Heart Failure. Circulation. 2019 01 08; 139(2):222-225.
    View in: PubMed
    Score: 0.013
  31. Aging, cardiac repair and Smad3. Aging (Albany NY). 2018 09 20; 10(9):2230-2232.
    View in: PubMed
    Score: 0.013
  32. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019 02; 65:70-99.
    View in: PubMed
    Score: 0.013
  33. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H934-H949.
    View in: PubMed
    Score: 0.013
  34. Targeting mitochondrial calcium transport in myocardial infarction. Hellenic J Cardiol. 2018 Jul - Aug; 59(4):223-225.
    View in: PubMed
    Score: 0.013
  35. Galectin-3 in the fibrotic response: Cellular targets and molecular mechanisms. Int J Cardiol. 2018 05 01; 258:226-227.
    View in: PubMed
    Score: 0.013
  36. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018 05; 175(9):1377-1400.
    View in: PubMed
    Score: 0.013
  37. Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker? Am J Physiol Heart Circ Physiol. 2018 06 01; 314(6):H1256-H1258.
    View in: PubMed
    Score: 0.013
  38. The Cellular Origin of Activated Fibroblasts in the Infarcted and Remodeling Myocardium. Circ Res. 2018 02 16; 122(4):540-542.
    View in: PubMed
    Score: 0.013
  39. Cell therapy for peripheral artery disease. Curr Opin Pharmacol. 2018 04; 39:27-34.
    View in: PubMed
    Score: 0.013
  40. Tissue transglutaminase in the pathogenesis of heart failure. Cell Death Differ. 2018 03; 25(3):453-456.
    View in: PubMed
    Score: 0.012
  41. Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc Res. 2017 Oct 01; 113(12):1453-1464.
    View in: PubMed
    Score: 0.012
  42. Left atrial remodeling, hypertrophy, and fibrosis in mouse models of heart failure. Cardiovasc Pathol. 2017 Sep - Oct; 30:27-37.
    View in: PubMed
    Score: 0.012
  43. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017 May 01; 127(5):1600-1612.
    View in: PubMed
    Score: 0.012
  44. Editor's Choice- Activation of the innate immune system in the pathogenesis of acute heart failure. Eur Heart J Acute Cardiovasc Care. 2018 Jun; 7(4):358-361.
    View in: PubMed
    Score: 0.012
  45. Immune cells in repair of the infarcted myocardium. Microcirculation. 2017 01; 24(1).
    View in: PubMed
    Score: 0.012
  46. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res. 2016 06 24; 119(1):91-112.
    View in: PubMed
    Score: 0.011
  47. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016 Jan; 90:84-93.
    View in: PubMed
    Score: 0.011
  48. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015 Sep 20; 5(4):1841-75.
    View in: PubMed
    Score: 0.011
  49. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res. 2016 Jan; 167(1):152-66.
    View in: PubMed
    Score: 0.010
  50. Mediators secreted by myeloid cells may protect and repair the infarcted myocardium. Circ Res. 2015 Jun 19; 117(1):10-2.
    View in: PubMed
    Score: 0.010
  51. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol. 2015 May; 30(3):240-5.
    View in: PubMed
    Score: 0.010
  52. Targeting the transforming growth factor (TGF)-? cascade in the remodeling heart: benefits and perils. J Mol Cell Cardiol. 2014 Nov; 76:169-71.
    View in: PubMed
    Score: 0.010
  53. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014 Oct; 164(4):323-35.
    View in: PubMed
    Score: 0.010
  54. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014 May; 11(5):255-65.
    View in: PubMed
    Score: 0.010
  55. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol. 2014 Mar; 63(3):185-95.
    View in: PubMed
    Score: 0.010
  56. Targeting the chemokines in cardiac repair. Curr Pharm Des. 2014; 20(12):1971-9.
    View in: PubMed
    Score: 0.009
  57. Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol. 2014 May; 70:74-82.
    View in: PubMed
    Score: 0.009
  58. MicroRNAs and endothelial function: many challenges and early hopes for clinical applications. J Am Coll Cardiol. 2014 Apr 29; 63(16):1695-6.
    View in: PubMed
    Score: 0.009
  59. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013 Sep; 43(9):986-95.
    View in: PubMed
    Score: 0.009
  60. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014 Feb; 71(4):549-74.
    View in: PubMed
    Score: 0.009
  61. The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res. 2012 Dec; 5(6):837-47.
    View in: PubMed
    Score: 0.009
  62. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta. 2013 Apr; 1833(4):945-53.
    View in: PubMed
    Score: 0.009
  63. Monomeric C-reactive protein and inflammatory injury in myocardial infarction. Cardiovasc Res. 2012 Oct 01; 96(1):4-6.
    View in: PubMed
    Score: 0.009
  64. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012 Apr; 92(2):635-88.
    View in: PubMed
    Score: 0.008
  65. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res. 2012 Apr; 159(4):197-204.
    View in: PubMed
    Score: 0.008
  66. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012 Jan 06; 110(1):159-73.
    View in: PubMed
    Score: 0.008
  67. TGF-? signaling in fibrosis. Growth Factors. 2011 Oct; 29(5):196-202.
    View in: PubMed
    Score: 0.008
  68. Stromal cell-derived factor-1-mediated angiogenesis for peripheral arterial disease: ready for prime time? Circulation. 2011 Mar 29; 123(12):1267-9.
    View in: PubMed
    Score: 0.008
  69. Transforming growth factor (TGF)-? signaling in cardiac remodeling. J Mol Cell Cardiol. 2011 Oct; 51(4):600-6.
    View in: PubMed
    Score: 0.008
  70. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev. 2010 Sep; 15(5):415-22.
    View in: PubMed
    Score: 0.007
  71. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol. 2010 Mar; 48(3):504-11.
    View in: PubMed
    Score: 0.007
  72. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed). 2009 06 01; 1(2):391-405.
    View in: PubMed
    Score: 0.007
  73. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009 May-Jun; 57(3):165-76.
    View in: PubMed
    Score: 0.007
  74. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009 Mar; 11(2):131-8.
    View in: PubMed
    Score: 0.007
  75. The immune system and cardiac repair. Pharmacol Res. 2008 Aug; 58(2):88-111.
    View in: PubMed
    Score: 0.006
  76. The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 27; 50(22):2125-7.
    View in: PubMed
    Score: 0.006
  77. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets. 2007 Jun; 6(2):101-7.
    View in: PubMed
    Score: 0.006
  78. Chemokines in ischemia and reperfusion. Thromb Haemost. 2007 May; 97(5):738-47.
    View in: PubMed
    Score: 0.006
  79. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem. 2007 Jan; 5(1):21-7.
    View in: PubMed
    Score: 0.006
  80. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006 Nov-Dec; 8(11-12):1907-39.
    View in: PubMed
    Score: 0.006
  81. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007 May 01; 74(2):184-95.
    View in: PubMed
    Score: 0.006
  82. Identification of mast cells in the cellular response to myocardial infarction. Methods Mol Biol. 2006; 315:91-101.
    View in: PubMed
    Score: 0.005
  83. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2006; 13(16):1877-93.
    View in: PubMed
    Score: 0.005
  84. Chemokines in myocardial ischemia. Trends Cardiovasc Med. 2005 Jul; 15(5):163-9.
    View in: PubMed
    Score: 0.005
  85. Targeting the chemokines in myocardial inflammation. Circulation. 2004 Sep 14; 110(11):1341-2.
    View in: PubMed
    Score: 0.005
  86. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol. 2004 Apr; 2(2):163-74.
    View in: PubMed
    Score: 0.005
  87. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy. 2003 Sep; 2(3):242-56.
    View in: PubMed
    Score: 0.005
  88. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol. 2002 May 01; 39(9):1468-74.
    View in: PubMed
    Score: 0.004
  89. Evidence for an active inflammatory process in the hibernating human myocardium. Am J Pathol. 2002 Apr; 160(4):1425-33.
    View in: PubMed
    Score: 0.004
  90. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002 Jan; 53(1):31-47.
    View in: PubMed
    Score: 0.004
  91. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res. 2019 06 01; 115(7):1117-1130.
    View in: PubMed
    Score: 0.003
  92. Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016 10 28; 119(10):1040-1045.
    View in: PubMed
    Score: 0.003
  93. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014 Feb 28; 114(5):872-88.
    View in: PubMed
    Score: 0.002
  94. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2700-5.
    View in: PubMed
    Score: 0.001
  95. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation. 2003 Feb 04; 107(4):538-44.
    View in: PubMed
    Score: 0.001
  96. Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIbbeta3 and alphaMbeta2, in coronary stenting. Thromb Res. 2003; 111(3):171-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.